Yunita, Ema P.
Indonesian Journal of Clinical Pharmacy

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Hubungan antara Obesitas, Konsumsi Tinggi Purin, dan Pengobatan terhadap Kadar Asam Urat dengan Penggunaan Allopurinol pada Pasien Hiperurisemia Yunita, Ema P.; Fitriana, Dinar I.; Gunawan, Atma
Indonesian Journal of Clinical Pharmacy Vol 7, No 1 (2018)
Publisher : Indonesian Journal of Clinical Pharmacy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (228.325 KB) | DOI: 10.15416/ijcp.2018.7.1.1

Abstract

Hiperurisemia adalah kondisi ketika kadar asam urat dalam darah melebihi nilai normal. Terdapat banyak faktor yang memengaruhi peningkatan kadar asam urat, seperti obesitas, konsumsi tinggi purin, dan pengobatan. Tujuan dari penelitian ini adalah untuk mengetahui hubungan antara obesitas, konsumsi tinggi purin, dan pengobatan terhadap kadar asam urat dengan penggunaan allopurinol pada pasien hiperurisemia. Data diperoleh melalui rekam medis dan kuesioner dari RSUD Dr. Saiful Anwar, Malang, dan dengan studi potong melintang. Pengambilan sampel dilakukan selama satu bulan (April–Mei 2014). Data dianalisis secara deskriptif dan diuji hipotesis. Sampel penelitian ini adalah 45 pasien hiperurisemia yang memperoleh allopurinol sebagai terapinya selama satu bulan dan pasien dipilih dengan metode pengambilan sampel konsekutif. Hasil dari penelitian ini menunjukkan bahwa tidak terdapat hubungan komparasi yang bermakna secara statistik antara kadar asam urat terhadap obesitas (0,193), konsumsi tinggi purin yaitu makanan laut (0,420), daging (0,469), jerohan (0,054), dan polong-polongan (0,398) juga pengobatan yaitu furosemid (0,631), aspirin dosis rendah (0,773), hidroklorotiazid (0,216), dan spironolakton (0,246). Selain itu, tidak pula terdapat korelasi yang bermakna secara statistik antara kadar asam urat terhadap obesitas (0,197), konsumsi tinggi purin yaitu makanan laut (0,426), daging (0,476), jerohan (0,053), dan polong-polongan (0,404) juga pengobatan yaitu furosemid (0,637), aspirin dosis rendah (0,776), hidroklorotiazid (0,220), dan spironolakton (0,250).Kata kunci: Allopurinol, asam urat, penghambat xantin oksidase Associations between Obesity, High Purine Consumptions, and Medications on Uric Acid Level with the Use of Allopurinol in Hyperuricemia PatientsHyperuricemia is a condition when the blood uric acid level exceeds the normal amount. There are many factors that can increase the uric acid level, such as obesity, high purine consumptions, and medications. The aim of this study was to determine the associations between obesity, high purine consumptions, and medications on uric acid level with the use of allopurinol in hyperuricemia patients. Data were collected through medical records and questionnaires from General Hospital of Dr. Saiful Anwar, Malang, and delivered within a cross-sectional study. Sampling was conducted for one month (April–May 2014). Data were analyzed descriptively and tested hypothetically. The samples of this study were 45 hyperuricemia patients who had gotten allopurinol as their therapy for a month and they were choosen by the consecutive sampling method. The results of this study showed that there were no statistically significant comparative association between uric acid level on obesity (0.193), high purine consumptions i.e. seafoods (0.420), meats (0.469), organ meats (0.054), and pods (0.398) also medications i.e. furosemide (0.631), low dose aspirin (0.773), hydrochlorotiazide (0.216), and spironolactone (0.246). In particular, there were no statistically significant correlations between uric acid level on obesity (0.197), high purine consumptions i.e. seafoods (0.426), meats (0.476), organ meats (0.053), and pods (0.404) also medicines i.e. furosemide (0.637), low dose aspirin (0.776), hydrochlorotiazide (0.220), and spironolactone (0.250).Keywords: Allopurinol, uric acid, xanthin oxidase inhibitor
Resistensi Aspirin pada Pasien Penyakit Jantung Koroner dengan Hipertensi Yunita, Ema P.; Zulkarnain, Bambang S.; Aminuddin, Muhammad
Indonesian Journal of Clinical Pharmacy Vol 4, No 1 (2015)
Publisher : Indonesian Journal of Clinical Pharmacy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (285.925 KB) | DOI: 10.15416/ijcp.2015.4.1.28

Abstract

Aspirin adalah terapi antiplatelet standar untuk penyakit jantung dan pembuluh darah. Aspirin dapat memberikan efek antiplatelet melalui asetilasi siklooksigenase di platelet sehingga menimbulkan hambatan pembentukan platelet yang permanen. Namun, aktivitas antiplatelet pada setiap individu dapat bervariasi. Penelitian di luar Indonesia memperkirakan sekitar 5 sampai 45% dari populasi tidak memperoleh efek antiplatelet yang adekuat dari aspirin. Penelitian tentang resistensi aspirin belum pernah dilakukan di RS Indonesia. Penelitian ini dilakukan untuk melihat prevalensi resistensi aspirin dan mengetahui faktor-faktor yang dapat memengaruhi resistensi aspirin pada pasien penyakit jantung koroner dengan komorbid hipertensi menggunakan metode agregasi platelet optik. Penelitian ini menggunakan studi potong lintang dengan melibatkan 43 pasien di Rumah Sakit Dr. Soetomo Surabaya selama bulan Juni 2012. Hasil penelitian menunjukkan tidak diperoleh pasien dengan resistensi aspirin dan hanya dua (4,7%) pasien termasuk aspirin semirespon. Respon pasien penyakit jantung coroner (PJK) dengan komorbid hipertensi terhadap aspirin sebagai antiplatelet masih bagus. Diperlukan penelitian serupa dengan sampel yang lebih besar pada pasien PJK disertai dua atau lebih komorbid. Selain itu, diperlukan penelitian lanjutan untuk mengetahui genotipe diantara pasien yang memberikan respon bagus dan pasien yang memberikan respon kurang terhadap aspirin.Kata kunci: Agregasi platelet, hipertensi, penyakit jantung koroner, resistensi aspirinAspirin Resistance in Coronary Artery Disease with Hypertensive PatientsAspirin is gold standard for antiplatelet therapy in cardiovascular treatment today. It exerts its antiplatelet effect by acetylation of the platelet cyclooxygenase, resulting in an irreversible inhibition of plateletdependent thromboxane formation. However, aspirin has been shown to have variable antiplatelet activity in individual patients. Previous studies estimated that 5% to 45% of population do not achieve an adequate antiplatelet effect from aspirin. Studies about aspirin resistance have never been done in Indonesian hospitals. This study was initiated to investigate the prevalence of aspirin resistance and influencing factors of aspirin resistance in coronary artery disease with hypertensive patients by using an established method of optical platelet aggregation. Fourty three patients were involved in this study. The sampling of this cross sectional study was conducted at Dr. Soetomo Hospital Surabaya in June 2012. Of the patients studied, there were no aspirin resistant and only 2 (4.7%) were aspirin semiresponders. It can be concluded that coronary artery disease patients with hypertension to aspirin as antiplatelet agent were good. Similar research is needed to be conducted with more sample sizes in coronary artery diseasepatients with two or more comorbid. In addition, further research is needed to determine genotyping between good or poor patient’s respond to aspirin.Keywords: Aspirin resistance, coronary artery disease, hypertensive, platelet aggregation